

What's This?
Intensively treating patients with diabetes to achieve American Diabetes Association-recommended targets for hemoglobin A1C, blood pressure (BP), and lipids significantly lowers their risk of new-onset microalbuminuria, suggesting such treatment can delay or prevent diabetic nephropathy, new data from a study conducted in Taiwan reveal. The longitudinal cohort study included 1,290 patients with type 2 diabetes, normoalbuminuria, and normal plasma creatinine levels at baseline (men, n=578;...
Intensively treating patients with diabetes to achieve American Diabetes Association-recommended targets for hemoglobin A1C, blood pressure (BP), and lipids significantly lowers their risk of new-onset microalbuminuria, suggesting such treatment can delay or prevent diabetic nephropathy, new data from a study conducted in Taiwan reveal.
The longitudinal cohort study included 1,290 patients with type 2 diabetes, normoalbuminuria, and normal plasma creatinine levels at baseline (men, n=578; mean age, 63 years; mean duration of diabetes, 10.1 years). During the study, the participants were treated to achieve A1C levels <7%, systolic BP <130 mm Hg, diastolic BP <80 mm Hg, LDL cholesterol levels <100 mg/dL, triglyceride levels <150 mg/dL, and HDL cholesterol levels >40 mg/dL in men and >50 mg/dL in women, with follow-up visits scheduled every 3 to 6 months.
During a mean follow-up of 3.8 years, 211 patients (16.4%) developed new-onset microalbuminuria.
The data showed that the patients who achieved target levels for systolic BP, A1C, or HDL cholesterol during follow-up were significantly less likely to develop new-onset microalbuminuria. Specifically, achieving a systolic BP <130 mg/dL was associated with a 35% reduction in risk, achieving an A1C level <7% was associated with a 27% reduction in risk, and achieving appropriate levels of HDL cholesterol was associated with a 28% reduction in risk in an analysis adjusted for age, sex, medication use, and body mass index.
When the analysis was further adjusted for baseline variables, including systolic BP, diastolic BP, A1C, lipids, creatinine, diabetes duration, albumin-creatinine ratio, and estimated glomerular filtration rate, these associations were attenuated. In this analysis, only a systolic BP <130 mg/dL was associated with a significant reduction in risk; the patients who achieved this systolic BP target during follow-up were 26% less likely to develop new-onset microalbuminuria relative to those who did not reach this goal.
Of the three goals associated with a significantly reduced risk of microalbuminuria (systolic BP, A1C, and HDL cholesterol), 8.1% of the participants achieved all 3 goals during follow-up, 71.4% achieved 1 or 2 of these goals, and 20.5% achieved none of these goals. The patients who achieved 2 or 3 goals were significantly less likely to develop microalbuminuria relative to those who achieved none. (Tu S-T, et al. Arch Intern Med 2010;170:155-161.)
What's This?
New data from the Adult Changes in Thought (ACT) study suggest elevated systolic blood pressure (SBP) may be a risk factor for the development of cerebral microinfarcts. However, findings from the study also suggest that treatment for hypertension may modify this association.
What's This?
Among patients with chronic kidney disease (CKD), lanthanum carbonate reduces serum phosphorus to a greater extent than sevelamer hydrochloride, new trial data reveal. However, statistically significant reductions were only observed in the subgroup of patients who completed treatment.
What's This?
Regardless of the antihypertensive treatment used, researchers found that the risk of hyperkalemia is inversely related to glomerular filtration rate (GFR) and body mass index (BMI) in nondiabetic black patients who have hypertensive chronic kidney disease.
What's This?
Reducing blood pressure (BP) with the combination of an angiotensin-converting enzyme inhibitor and a diuretic seems to reduce the risk of renal events in patients with type 2 diabetes, even in patients with BP levels below currently recommended targets, according to an analysis of renal outcomes in the ADVANCE trial.